Navigation Links
deCODE Announces Positive Topline Results for Phase I Study of,DG051 for the Prevention of Heart Attack

ed by one of the genes in the leukotriene pathway deCODE has linked to increased risk of heart attack. The at-risk versions of these genes confer increased risk of heart attack by increasing the production of the pro-inflammatory molecule leukotriene B4 (LTB4). DG051 is designed to decrease risk of heart attack by decreasing the production of LTB4.

About deCODE

deCODE genetics is a global leader in applying human genetics to develop drugs and diagnostics for common diseases. Our population approach has enabled us to discover and target key biological pathways involved in conditions ranging from heart attack to cancer. We are turning these discoveries into new medicine to better treat and prevent many of the biggest challenges to public health. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com, and on our diagnostics site at http://www.decodediagnostics.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking
'"/>




Page: 1 2 3

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 /CNW/ - More than fifty ... to treat morning sickness in expectant mothers. Tragically, Thalidomide caused ... and families. Support has been provided to ... Government of Canada in 1991 and ... absence of a legal obligation to provide support, we have ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... Administration (FDA) approved the use of once-daily INTUNIV® (guanfacine) ... treatment of attention deficit hyperactivity disorder (ADHD) in children and ... treatment program. The approval is based on results from a ...
... specialist in genome customization and subsidiary of Cellectis (Alternext: ... custom TALEN(1). Recognized as a pioneer in ... Cellectis bioresearch brings today the life sciences community a ... of cell. The service will start with ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Cellectis bioresearch Makes Genome Engineering Affordable for All Users 2
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin ... ProPin to pin point locations on a map, to indicate prices ... allows users to choose from 30 simplistic presets with geometric design ... video editors can easily manipulate ProPin presets as a whole. ... ease. , Using ProPin is easy, simply drag a preset into ...
(Date:5/24/2015)... May 24, 2015 A report ... that the single best option for avoiding cardiovascular disease ... fitness level was the single most powerful predictor of ... such as diabetes and family history of premature death ... lifelong heart and lung fitness. , The Importance of ...
(Date:5/23/2015)... 23, 2015 With the implementation of ... finding it increasingly difficult to provide their employees with ... provide adequate insurance for employees stand to face strict ... an integral part of a business’s success or failure. ... businesses, Online USA Doctors has created a varying level ...
(Date:5/23/2015)... A live auction will be held to sell ... and other medical facilities around the United States. Various ... surgery, anesthesia, exam and much more. , The live ... 28 starting at 9:00am CDT each day. The equipment is ... Melrose Park, IL 60160. Anyone can participate in the ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 ... technology, communication and capacity are intersecting to create ... across society, the opening speaker at WesternU's 34th ... California Lieut. Gov. Gavin Newsom, a former San ... the keynote speaker at the graduation ceremony for ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3
... a recently-formed, New Jersey-based biotechnology company, applies ... scale protein production, Nuclear Magnetic Resonance (NMR), ... discovery efforts. Nexomics Biosciences has signed ... State University of New Jersey, that provides ...
... Jan. 20 Nationwide Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for ... year 2008:, COMMON STOCK (CUSIP# 638620104), 2008 ... Taxable Return Total Unrecaptured, ... Capital Section, Date ...
... Usage of Controversial App , ... (PRWEB) January 20, ... there is some very unfortunate confusion as to the intentions of ... entitled "Teen Torture". Due to its attention-grabbing name, and the ...
... Inc. (Nasdaq: OMCL ), a leading provider ... its 2008 year end guidance and provided initial guidance ... a reorganization focused on driving sales through higher levels ... results to be consistent with previous guidance of 18% ...
... offer doctors a better assessment of patient,s condition, chances of ... images of post-heart attack bleeding within the heart have been ... College London team said their research shows that the amount ... a heart attack. The use of this kind of imaging, ...
... While the U.S. Food and Drug Administration (FDA) and ... week,s Peanut Corporation of America (PCA) recall it is important ... of jarred peanut butter are not affected by the PCA ... , , In addition, although some food ...
Cached Medicine News:Health News:New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground 2Health News:New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground 3Health News:NHP Announces Tax Treatment of 2008 Distributions 2Health News:NHP Announces Tax Treatment of 2008 Distributions 3Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 3Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 2Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 3Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 4Health News:Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization 5Health News:MRI Scans Reveal Post-Heart Attack Bleeding 2
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Valproic Acid in human serum...
For the quantitative in vitro determination of Microalbumin in human urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Medicine Products: